Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Fractures: Bone Repair

Fractures: Bone Repair

Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the procedure...

Bone Disorders

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

Osteoclasts in Bone Remodeling

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...

Bone Remodeling and Repair

Bone Remodeling and Repair

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...

Bone Formation by Intramembranous Ossification

Bone Formation by Intramembranous Ossification

Intramembranous ossification is one of the two processes involved in the development of bones within an embryo. The flat bones of the face, most of the cranial bones, and the clavicles are formed via this process. During intramembranous ossification, the bones develop directly from sheets of undifferentiated mesenchymal connective tissue.
The process begins when mesenchymal cells in the embryonic skeleton gather together and differentiate into osteogenic cells, which then develop into...

Bone Formation by Endochondral Ossification

Bone Formation by Endochondral Ossification

Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

UK consensus guidelines for multidisciplinary care of children and young people with achondroplasia: a modified Delphi process.

Archives of disease in childhood·2026

Same author

Bone microstructural and strength changes over 1 year in children with osteogenesis imperfecta are comparable to age- and sex-matched healthy controls.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025

Same author

The Head Circumference Height Index (HCH-I) to Quantify Relative Macrocephaly and Aid Identification of Hypochondroplasia in Children.

American journal of medical genetics. Part A·2025

Same author

XLH Matters 2024: expert insights and practical tools for enhancing care of people living with X-linked hypophosphataemia.

Orphanet journal of rare diseases·2025

Same author

Limb lengthening in individuals with achondroplasia: Analysis of an international survey.

Bone·2025

Same author

XLH Matters: an evolving programme to discuss new advances and share clinical experiences to improve patient outcomes.

Orphanet journal of rare diseases·2025

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Creating Rigidly Stabilized Fractures for Assessing Intramembranous Ossification, Distraction Osteogenesis, or Healing of Critical Sized Defects

Creating Rigidly Stabilized Fractures for Assessing Intramembranous Ossification, Distraction Osteogenesis, or Healing of Critical Sized Defects

Published on: April 11, 2012

Osteogenesis Imperfecta: update on presentation and management.

Moira S Cheung¹, Francis H Glorieux

¹Genetics Unit, Shriners Hospital for Children and McGill University, Montréal, QC, Canada. mcheung@shriners.mcgill.ca

Reviews in Endocrine & Metabolic Disorders

|April 12, 2008

Summary

This summary is machine-generated.

Osteogenesis Imperfecta (OI) is a rare genetic disorder causing bone fragility. Recent discoveries in OI types V-VII and genetic mutations are improving diagnosis and treatment, with bisphosphonates like pamidronate and zoledronic acid being key therapies.

More Related Videos

Improved Methodology for Studying Postnatal Osteogenesis via Intramembranous Ossification in a Murine Bone Marrow Injury Model

Improved Methodology for Studying Postnatal Osteogenesis via Intramembranous Ossification in a Murine Bone Marrow Injury Model

Published on: February 7, 2025

Related Experiment Videos

Last Updated: Jul 6, 2026

Creating Rigidly Stabilized Fractures for Assessing Intramembranous Ossification, Distraction Osteogenesis, or Healing of Critical Sized Defects

Creating Rigidly Stabilized Fractures for Assessing Intramembranous Ossification, Distraction Osteogenesis, or Healing of Critical Sized Defects

Published on: April 11, 2012

Improved Methodology for Studying Postnatal Osteogenesis via Intramembranous Ossification in a Murine Bone Marrow Injury Model

Improved Methodology for Studying Postnatal Osteogenesis via Intramembranous Ossification in a Murine Bone Marrow Injury Model

Published on: February 7, 2025

Area of Science:

Genetics
Pediatrics
Orthopedics

Background:

Osteogenesis Imperfecta (OI) is a rare heritable disorder characterized by bone fragility and low bone mass.
Traditionally classified into types I-IV, OI's understanding has expanded with the identification of autosomal recessive forms (OI types V-VII) linked to mutations in genes like CRTAP and P3H1.
The wide phenotypic variation in OI presents diagnostic challenges, necessitating awareness of new forms and diagnostic tool limitations.

Purpose of the Study:

To review the evolving understanding of Osteogenesis Imperfecta (OI) pathophysiology, diagnosis, and management.
To highlight recent advancements in identifying genetic causes beyond collagen defects.
To discuss current and emerging therapeutic strategies for OI.

Main Methods:

Literature review of Osteogenesis Imperfecta (OI) classification, genetics, and treatment.
Analysis of diagnostic challenges and advancements.
Evaluation of bisphosphonate therapies, including pamidronate and zoledronic acid.

Main Results:

Discovery of new OI types (V-VII) and associated genetic mutations (e.g., CRTAP, P3H1) has broadened the understanding of OI pathophysiology.
Cyclical intravenous pamidronate is the standard care for moderate to severe pediatric OI, alongside comprehensive orthopedic and rehabilitation programs.
While short-term safety and benefits of bisphosphonates are established, long-term effects require further investigation. Newer agents like zoledronic acid are under trial.

Conclusions:

Accurate diagnosis and management of OI require awareness of its diverse phenotypes, new genetic forms, and diagnostic limitations.
Bisphosphonate therapy, particularly pamidronate, is effective for OI, with ongoing research into newer agents like zoledronic acid and their long-term outcomes.